biote (NASDAQ:BTMD) Issues Earnings Results

biote (NASDAQ:BTMD) issued its quarterly earnings data on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.26), FiscalAI reports. The firm had revenue of $44.23 million for the quarter, compared to analysts’ expectations of $46.12 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%.

Here are the key takeaways from biote’s conference call:

• Negative Sentiment: Second-quarter revenue fell 9.5% to $44.2 million, while procedure revenue declined 13.9% to $30.3 million, pressured by the voluntary pellet recall, supply constraints, clinic attrition, and slower new-clinic productivity.
• Negative Sentiment: Biote lowered its 2026 outlook to revenue above $175 million and adjusted EBITDA above $25 million, compared with prior guidance of more than $190 million and $38 million, respectively; year-over-year procedure revenue is now expected to remain negative in the second half.
• Positive Sentiment: Management said Asteria Health’s supply continuity and inventory levels have normalized, with a second production shift added; reduced reliance on higher-cost third-party pellets is expected to improve gross margins beginning in the third quarter.
• Neutral Sentiment: The company is entering a second strategic phase focused on clinic retention, practitioner engagement, sales-force productivity, and faster new-clinic ramp-up, while also evaluating disciplined inorganic opportunities that could expand its market footprint.
• Positive Sentiment: Dietary-supplement revenue increased 5.7% to $11.4 million, supported by e-commerce and strong adoption among existing clinicians, and is expected to grow at a mid- to high-single-digit rate for 2026; recently resolved legal matters should also reduce future expenses.

biote Price Performance

Shares of biote stock traded down $0.01 during trading on Wednesday, hitting $2.26. The stock had a trading volume of 78,781 shares, compared to its average volume of 247,289. biote has a 12 month low of $1.27 and a 12 month high of $4.15. The firm’s fifty day simple moving average is $2.21 and its 200-day simple moving average is $2.05. The stock has a market cap of $84.93 million, a PE ratio of 5.14 and a beta of 1.64.

Institutional Trading of biote

Institutional investors have recently added to or reduced their stakes in the company. First Trust Advisors LP grew its stake in shares of biote by 5.3% during the second quarter. First Trust Advisors LP now owns 73,669 shares of the company’s stock valued at $296,000 after buying an additional 3,675 shares during the last quarter. Man Group plc boosted its holdings in biote by 9.9% during the 3rd quarter. Man Group plc now owns 70,383 shares of the company’s stock valued at $211,000 after acquiring an additional 6,356 shares during the period. Geode Capital Management LLC increased its stake in biote by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 620,256 shares of the company’s stock worth $1,613,000 after purchasing an additional 8,016 shares during the period. Renaissance Technologies LLC lifted its position in shares of biote by 5.7% during the fourth quarter. Renaissance Technologies LLC now owns 203,594 shares of the company’s stock worth $529,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of biote by 54.3% during the fourth quarter. Wells Fargo & Company MN now owns 32,464 shares of the company’s stock worth $84,000 after purchasing an additional 11,427 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Truist Financial upgraded shares of biote to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings raised shares of biote from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $2.75.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.